Keating Financial Advisory Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Keating Financial Advisory Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$55.8K	Buy	975 +45	+5%	+$2.46K	0.01%	652
2026 Q1	$52.5K	Buy	930 +17	+2%	+$991	0.01%	607
2025 Q4	$54.3K	Buy	+913	New	+$49.7K	0.01%	634

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Keating Financial Advisory Services's BMRN Position: Q2 2026 in Review

Keating Financial Advisory Services increased its BioMarin Pharmaceuticals (BMRN) stake by 4.8% in Q2 2026, buying an estimated $2.46K and bringing the position to 975 shares worth $55.8K. The position accounts for 0.01% of the portfolio, ranked #652.

Keating Financial Advisory Services first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Keating Financial Advisory Services held 975 shares of BioMarin Pharmaceuticals worth $55.8K as of Q2 2026.
Keating Financial Advisory Services bought 45 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.46K.
BioMarin Pharmaceuticals made up 0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #652 holding.
Keating Financial Advisory Services first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.